FS118 + paclitaxel

FS118 + paclitaxel is a combination therapy undergoing clinical investigation for advanced cancers, specifically squamous cell carcinoma of the head and neck with resistance to PD-(L)1 inhibitors. **FS118** is a human tetravalent bispecific monoclonal antibody targeting both **LAG-3** and **PD-L1**: it blocks these immune checkpoints, overcoming immune suppression and resistance mechanisms to checkpoint monotherapies[2][4]. FS118 is engineered for bivalent LAG-3 binding and simultaneous PD-L1 blockade, leading to potent immune activation by promoting shedding of LAG-3, reducing its surface expression on T cells, and reinvigorating antitumor immunity[2][4]. **Paclitaxel** is a well-established antineoplastic small molecule that stabilizes microtubules, causing mitotic arrest and cell death in rapidly dividing cancer cells[3]. The combination is being investigated for potential synergistic antitumor efficacy via immunomodulation and direct cytotoxicity.

Other names

FS118FS-118FS 118anti-LAG-3/PD-L1 bispecific antibodypaclitaxel